Online ISSN: 2582-6387
IP Journal of Surgery and Allied Sciences (JSAS) open access, peer-reviewed quarterly journal publishing since 2019 and is published under the Khyati Education and Research Foundation (KERF), is registered as a non-profit society (under the society registration act, 1860), Government of India with the vision of various accredited vocational courses in healthcare, education, paramedical, yoga, publication, teaching and research activity, with the aim of faster and better dissemination of knowledge, we will be publishing the article ‘Ahead more...Case Report
Author Details :
Volume : 1, Issue : 2, Year : 2019
Article Page : 42-45
Abstract
Myoepithelioma is a rare salivary gland neoplasm. It is seen around 1-1.5% among all salivary gland. Parotid gland is the most common site of occurrence. The second most common site is palatal minor salivary glands. This neoplasm came into literature long back but the histopathologic picture doesn’t seem to be well characterized. Many authors attribute the complexity of this neoplasm. The myoepithelial component that is seen between the basement membrane. It is also seen in the basal plasma membrane of acinar cells. Traditionally it's been represented that it consists of spindle myoepitheliocytes. Pathologically myoepithelioma is accepted as a specific entity. In this article, we are presenting a case of a 76-year-old male with salivary gland myoepithelioma, an especially rare entity. We have also given a brief description of its clinical and pathologic feature.
Keywords: Myoepithelioma, Parotid tumor, Salivary gland tumor.
How to cite : Dhirawani R B, Taank J, Zunzani I, Singha S, Myoepithelioma of parotid gland - A rare entity. IP J Surg Allied Sci 2019;1(2):42-45
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.